Risk alert: FDA recalls ranitidine

April 1, 2020 Gracie Awalt

April 1, 2020

The Food and Drug Administration has recalled all prescription and over-the-counter ranitidine products due to contamination.

The FDA found that ranitidine, known over-the-counter as Zantac, contains the contaminant N-Nitrosodimethylamine (NDMA). According to the FDA, NDMA may cause cancer if it is exposed to above room temperature conditions. The FDA has not found NDMA in famotidine, cimetidine, esomeprazole, lansoprazole, or omeprazole.

The FDA recommends the following.

  • Patients taking OTC ranitidine should stop taking it and dispose of it properly.
  • Patients taking prescription ranitidine medication should speak with their health care professional discuss alternative medications.  
  • In light of the COVID-19 pandemic, do not take recalled medications to a drug take-back location. Instead, follow these drug disposal guidelines provided by the FDA.

Report adverse events or side effects to the FDA's MedWatch Safety Information and Adverse Event Reporting Program by doing one of the following:

Previous Flipbook
Reporter Q1 2020
Reporter Q1 2020

CME: Risks associated with medical spas; TMLT Government Relations: Our focus for 2020; Failure to follow u...

Next Article
COVID-19: Medical liability FAQs
COVID-19: Medical liability FAQs

Answers to your questions about COVID-19 and medical liability.

COVID-19 Resources

See More